Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Survey: Half Of Companies Throw Big Bucks At FDA-483 Observations, While Heads Roll At A Quarter Of Firms After Poor Inspection Results

This article was originally published in The Gray Sheet

Executive Summary

A survey of 310 industry stakeholders found that extra resources are given to functional areas singled out by agency investigators for noncompliance at 49% of device firms, but respondents also said additional assets don't always equate to improved device quality. "The challenge for us in the quality area is to ensure that we understand what the appropriate amount of staffing is once we reach development of the processes that we need, and what we need as far as resources to maintain those processes," Meridian Bioscience's Susan Rolih says. Meanwhile, 24% of survey-takers say employees are fired or penalized when there are poor inspection outcomes – a knee-jerk reaction that experts say can negatively affect worker morale. Also: An overwhelming majority of survey respondents, 68%, say investigators should list observations on an FDA-483 from major to minor; 66% say they address the riskiest FDA observations first; 93% tackle so-called "discussion items"; and more.



Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts